To investigate if the use of initial NPWTi leads to a faster wound healing compared to standard wound care only in patients with a POWI.
ID
Source
Brief title
Condition
- Skin and subcutaneous tissue therapeutic procedures
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Primary outcome: Time to complete wound healing defined as re-epithelization of
the total wound surface or if the wound is ready for secondary surgical closure
(i.e. healthy red granulation tissue without signs of infection or debris).
Secondary outcome
Secondary outcomes:
• pain (using a Numeric Rating Scale (NRS) scored for the first two weeks
daily; and during dressing changes for the first four weeks);
• hospital length of stay (HLOS);
• hospital readmissions (wound-related) (within 30 and 90 days after
discharge);
• frequency and type of surgical procedures related to SSI within 90 days
post-operative;
• health-related quality of life (using the EQ-5D-5L) at baseline; and after 30
& 90 days, 6 and 12 months after inclusion);
• patient satisfaction (Numeric Rating Scale (NRS) ranging from 0-10 score);
• duration of total wound care, frequency of wound care (e.g., dressing
changes) (during admission);
• the need for homecare (and duration) for wound care after discharge from
hospital;
• costs (mean material costs per day; mean costs nursing time per dressing
change based Dutch tariff; iMTA Medical Consumption Questionnaire (iMCQ); the
iMTA Productivity Cost Questionnaire (iPCQ) at baseline and after 30 & 90 days,
6 and 12 months after inclusion;
• professional satisfaction (Numeric Rating Scale (NRS) ranging from 0-10
score).
Additionally, three planned subgroup analysis of wound healing will be
performed: (1) NPWT vs. conventional wound care within the standard care group;
and (2) wound healing after secondary surgical closure vs. no secondary
surgical closure; (3) foreign body-associated infections from implants of index
operation vs. no foreign body-associated infections from implants of index
operation.
Background summary
Surgical wounds are the most common wounds seen in daily clinical practice and
are associated with a variety of complications such as bleeding and dehiscence.
Surgical site infections are the most common complication, and the high rates
of POWI leads to additional treatment, prolonged hospital stay, patient
discomfort, and as a result of this a substantial increase in costs. Negative
Pressure Wound Therapy with Instillation (NPWTi) use is growing as a
therapeutic approach to treat postoperative wound infections (POWIs), yet high
quality evidence of its effectiveness is lacking. Our hypothesis is that time
to complete wound healing in patients with a POWI who receive NPWTi will be
shorter than in patients receiving standard wound care (i.e., NPWT and/or
conventional wound care).
Study objective
To investigate if the use of initial NPWTi leads to a faster wound healing
compared to standard wound care only in patients with a POWI.
Study design
An investigator-initiated multicentre randomized controlled trial. Patients
will be randomized to NPWTi or standard wound care with a 1:1 ratio. An a
priori power analysis and an anticipated dropout rate of 10% indicates that 223
patients per group are needed, totalling 446 patients to be able to detect a
14-day reduction in wound healing time.
Intervention
NPWTi (after debridement if needed). The wound will be covered with an
open-cell foam and an occlusive drape. During repeated cycles, the wound bed
will be automatically soaked with 0.9% normal saline for 15 minutes followed by
negative pressure cycle at -125 mmHg for 2-3 hours; cycle length depending on
the bioburden of the wound. The foam and drape are changed every 2-3 days (1
treatment period). At least two treatment periods of 2-3 days need to be
completed before switch to standard NPWT (preferred) or conventional dressing.
Comparison: Standard wound care (after debridement if needed). This involves
the use of NPWT and/or conventional dressings, depending on local standards.
NPWT involves open-cell foam and occlusive drape with negative pressure
treatment but without intermittent topical delivery of instillation fluid and
soaking cycles. Conventional dressings are gauze-based or occlusive dressings
and will be used until the wound is completely healed.
Study burden and risks
Patients will be asked to report pain scores (using a Numeric Rating Scale
(NRS) scored for the first two weeks daily, and during dressing changes for the
first four weeks) (in total: approximately 30 minutes). They will be also be
asked to complete the EQ-5D-5L health status questionnaire, the iMTA Medical
Consumption Questionnaire (iMCQ) and the iMTA Productivity Cost Questionnaire
(iPCQ) at baseline, and after 30 & 90 days, 6 and 12 months after inclusion)
(approximately 20 minutes per measurement), and to take photos of their wound
at baseline, and after 30 & 90 days, 6 and 12 months after inclusion) and
during dressing changes (approximately 5 minutes per measurement). NPWTi, NPWT
and conventional wound care are all used as a therapeutic aid to treat POWIs,
and are considered as safe interventions.
Meibergdreef 9
Amsterdam 1105AZ
NL
Meibergdreef 9
Amsterdam 1105AZ
NL
Listed location countries
Age
Inclusion criteria
In order to participate in this study, a subject must meet all of the following
criteria:
• Age equal or older than 18 years;
• A superficial or deep SSI plus a wound dehiscence (> 5 cm dehiscence) or a
wound that needs to be opened for drainage of SSI after any type of surgery;
• SSI occurring within 30 days after surgery;
• A minimum wound size of 10 cm² to allow proper application of the study
treatments;
• Written informed consent.
Exclusion criteria
A potential subject who meets any of the following criteria will be excluded
from participation in this study:
• A deep organ/space SSI without a superficial (involvement of skin and fascia)
wound infection
• Psychically or mentally inability for informed consent
• Fascial dehiscence > 0,5 cm
Design
Recruitment
Medical products/devices used
Kamer G4-214
Postbus 22660
1100 DD Amsterdam
020 566 7389
mecamc@amsterdamumc.nl
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL76838.018.21 |